Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Astellas Pharma has received a Japanese marketing approval for the immunosuppressant Graceptor Capsules 0.5mg, 1mg and 5mg for suppression of organ rejection and suppression of graft rejection and graft-versus-host disease in bone marrow transplantation.
Subscribe to our email newsletter
Graceptor is a once-daily modified release formulation of Astella’s Prograf (tacrolimus, twice-daily formulation). Tacrolimus works as an immunosuppressant by inhibiting production of cytokinine including differentiation or growth factor secreted from T-cell, interleukin-2 and interferon-gamma.
Once daily formulation of Graceptor is expected to improve long-term compliance with its more convenient once-daily dosing option, and may have the potential to reduce the incidence of graft loss.
Astellas expects to provide a new option for transplant medication with the new line-up for Prograf family. The launch timing will be announced after it appears in the NHI drug price list.